Changes in urinary excretion of water and sodium transporters during amiloride and bendroflumethiazide treatment

Table 4 Effect of 3% hypertonic saline on plasma in 23 healthy subjects treated with bendroflumethiazide or amiloride

Time	Baseline	Infusion	Post infusion			PGLM-RM
	0-90 min	150 min	180 min	210 min	240 min
p-Na						0.281
BFTZ	137 ± 2	141 ± 2d	141 ± 2d	139 ± 2d	139 ± 2d
Amilorid	137 ± 2	141 ± 2d	141 ± 2d	140 ± 2d	139 ± 2d
Placebo	139 ± 1	43 ± 2d	142 ± 1d	141 ± 1d	140 ± 1d
PGLM between subjects 0.003
PANOVA	0.001	0.019	0.004	0.007	0.005
p-K						0.001
BFTZ	3.35 ± 0.22	3.32 ± 0.23	3.43 ± 0.26	3.42 ± 0.21	3.40 ± 0.20
Amilorid	4.32 ± 0.30	4.17 ± 0.23d	4.26 ± 0.27	4.27 ± 0.25	4.20 ± 0.20a
Placebo	3.89 ± 0.18	3.83 ± 0.22	3.97 ± 0.23	3.94 ± 0.22	3.92 ± 0.20
PGLM between subjects < 0.0001
PANOVA	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001
p-Osm						0.600
BFTZ	281 ± 5	288 ± 4d	288 ± 6d	286 ± 5d	284 ± 4d
Amilorid	283 ± 4	290 ± 4d	290 ± 3d	287 ± 3d	285 ± 3a
Placebo	286 ± 3	294 ± 4d	292 ± 4d	290 ± 4d	289 ± 3b
PGLM between subjects < 0.0001
PANOVA	< 0.001	< 0.001	0.005	0.002	< 0.001
p-Alb (g/L)						0.007
BFTZ	40.7 ± 3.1	35.5 ± 2.2d	35.9 ± 2.7d	36.0 ± 2.8d	36.0 ± 2.7d
Amilorid	40.9 ± 2.9	35.5 ± 2.3d	36.4 ± 2.6d	36.4 ± 2.7d	36.3 ± 2.5d
Placebo	39.0 ± 2.4	34.5 ± 2.0d	35.1 ± 2.2d	35.1 ± 2.3d	35.3 ± 2.4d
PGLM between subjects 0.203

Plasma concentrations of sodium (p-Na), potassium (p-K) and albumin (p-Alb) and plasma osmolality (p-osm). Values are mean ± SD. General linear model (GLM) with repeated measures was performed for comparison within the group and intervention as between subjects factor. One-way ANOVA was performed when differences were found between interventions. Bonferroni correction was used for multiple comparisons between study-periods vs baseline.

^aP < 0.05;

^bP < 0.01;

^dP < 0.001.